Combination of Envafolimab and Platinum-Based Chemotherapy as a potential First‑line regimen for Lung Cancer: systematic review and meta‑analysis

MINORS) checklist was used to assess the quality of the included studies. Strategy of data synthesisAll statistical analyses were performed using STATA software version 15.1 (STATA, College Station, Texas 77845 USA).The metaprop command was used to perform a metaanalysis, in which data were pooled to calculate odds ratios (OR) and their 95% confidence intervals (CI), and a forest plot was generated for visualization.A Q test with P > 0.05 or I² < 50% i n d i c a t e d t h a t t h e re w a s n o s i g n i fi c a n t heterogeneity among the studies, so a fixed-effect model was adopted; otherwise, a random-effects model was used. Subgroup analysisSubgroup analyses were conducted based on Accepted Line of Therapy (0 or ≥1), Medications of Intervention (whether Envafolimab was used in combination with chemotherapy, whether it was combined with platinum-based chemotherapy, and whether it was combined with platinum-based chemotherapy and different targeted drugs)and Pathologic Subtype.Sensitivity analysis Sensitivity analysis was performed using the metainf command in Stata software to assess the reliability of the data.Sensitivity analysis was performed using the metainf command to assess the reliability of the data. Country(ies) involvedChina.